Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01028820 · ClinicalTrials.gov registry record · Phase 4
FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT01028820 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 13 participants.
The verdict
NCT01028820, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is an 8 week research study of aripiprazole (abilify) which is used to reduce irritable behaviors in autism spectrum disorders. All participants will receive active study medication. Participants will also receive diagnostic and cognitive evaluations at no cost. Participants will be required to undergo two fMRI (functional magnetic resonance imaging scans) where we will take pictures of your brain while performing simple tasks.
Interventions
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01028820
The ClinicalTrials.gov registry entry for NCT01028820 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole is the first listed.
NCT01028820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01028820 about?
NCT01028820 is a clinical study titled "FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders". This is an 8 week research study of aripiprazole (abilify) which is used to reduce irritable behaviors in autism spectrum disorders. All participants will receive active study medication. Participants will also receive diagnostic and cognitive evaluations at no cost. Participants will be required to...
What is the current status of trial NCT01028820?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2009-08. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01028820?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT01028820?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.